Is Xospata used for FLT3-mutated AML?

What is Xospata, and what type of AML does it treat?

Xospata, also known as gilteritinib, is a small molecule tyrosine kinase inhibitor [1] used in the treatment of adults with a type of blood cancer called acute myeloid leukemia (AML). According to DrugPatentWatch.com, Xospata was approved by the FDA in January 2019 for the treatment of relapsed or refractory FLT3-mutated AML [2].

FLT3-mutated AML: a complex and challenging disease

FLT3 (Fms-related tyrosine kinase 3) mutations are present in a subset of AML patients, approximately 25-30% of all AML cases [3]. These mutations can lead to a rapid progression of the disease and are associated with poor outcomes. Xospata has been shown to be effective in reducing the risk of disease progression and improving overall survival in FLT3-mutated AML patients [4].

Xospata's mechanism of action

Xospata works by inhibiting the activity of the FLT3 tyrosine kinase, a protein that is involved in the development and growth of cancer cells [5]. By blocking this protein, Xospata can help to slow down the growth of cancer cells and reduce the risk of disease progression.

Key takeaways

- Xospata is specifically designed to target FLT3-mutated AML.
- The FDA approved Xospata in 2019 for the treatment of relapsed or refractory FLT3-mutated AML.
- Clinical trials have shown Xospata to be effective in improving outcomes for patients with FLT3-mutated AML.

Sources:
[1] Wikipedia - Gilteritinib
[2] DrugPatentWatch.com - Gilteritinib (Xospata)
[3] National Cancer Institute - Acute Myeloid Leukemia Treatment (PDQ®) - FLT3 Mutation
[4] ClinicalTrials.gov - A Study of Gilteritinib (Xospata) in Patients With Relapsed or Refractory FLT3-mutated Acute Myeloid Leukemia (APL-1)
[5] ScienceDirect - Gilteritinib: A Review of Its Use in the Treatment of FLT3-Mutated Acute Myeloid Leukemia